Canada - Français
The Trial Assigning Individualized Options for Treatment (TAILORx) primary study group results were published in The New England Journal of Medicine
See You at ASCO 2018!
June 1–5 | Chicago, IL | McCormick Place | Booth 12089
At Genomic Health, we always look forward to the American Society of Clinical Oncology's annual meeting. This year's meeting promises to be exceptional in the quality and quantity of new research in genomics, and we hope to see you there!
A large, independent study using the Oncotype DX Breast Recurrence Score® test has been accepted for presentation at ASCO 2018.
Over 900,000 cancer patients worldwide have benefited from Oncotype DX tests. Hear from oncologists and allied medical professionals about their experiences with the test.
Follow us on Twitter to hear about all the latest updates from ASCO.